

Usha Nayak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3350977/publications.pdf>

Version: 2024-02-01

74
papers

2,260
citations

218677
26
h-index

233421
45
g-index

75
all docs

75
docs citations

75
times ranked

3305
citing authors

#	ARTICLE	IF	CITATIONS
1	Repositioning of antidiabetic drugs for Alzheimer's disease: possibility of Wnt signaling modulation by targeting LRP6 an <i>in silico</i> based study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 9577-9591.	3.5	5
2	Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex. Chemical Papers, 2022, 76, 1063-1083.	2.2	9
3	Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis. Life Sciences, 2022, 291, 120283.	4.3	18
4	Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer's disease. Molecular Diversity, 2022, 26, 2793-2811.	3.9	8
5	Recent Updates on Nanocosmeceutical Skin Care and Anti-Aging Products. Current Pharmaceutical Design, 2022, 28, 1258-1271.	1.9	7
6	Understanding the Effect of Functionalization on Loading Capacity and Release of Drug from Mesoporous Silica Nanoparticles: A Computationally Driven Study. ACS Omega, 2022, 7, 8229-8245.	3.5	9
7	Enhancing the oral bioavailability of asenapine maleate with bio-enhancer: An in-silico assisted in-vivo pharmacokinetic study. Journal of Drug Delivery Science and Technology, 2022, 70, 103215.	3.0	2
8	Hybrid nanostructures: Versatile systems for biomedical applications. Coordination Chemistry Reviews, 2022, 460, 214482.	18.8	25
9	Comparative Evaluation of the Effectiveness of a Combination of Absorbable Gelatin Sponge and Calendula officinalis with Absorbable Gelatin Sponge Used Alone as a Hemostatic Agent—An In-Vitro Study. Dentistry Journal, 2022, 10, 76.	2.3	2
10	Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 2021, , 1-10.	3.5	14
11	Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Archives of Medical Research, 2021, 52, 38-47.	3.3	46
12	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. Molecular Diversity, 2021, 25, 1905-1927.	3.9	29
13	Long-Acting Formulations: A Promising Approach for the Treatment of Chronic Diseases. Current Pharmaceutical Design, 2021, 27, 876-889.	1.9	2
14	SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. European Journal of Pharmacology, 2021, 896, 173922.	3.5	29
15	Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy. Carbohydrate Polymers, 2021, 261, 117893.	10.2	45
16	Lymphatic Drug Transport and Associated Drug Delivery Technologies: A Comprehensive Review. Current Pharmaceutical Design, 2021, 27, 1992-1998.	1.9	7
17	Structurally nanoengineered antimicrobial peptide polymers: design, synthesis and biomedical applications. World Journal of Microbiology and Biotechnology, 2021, 37, 139.	3.6	3
18	Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy. International Journal of Pharmaceutics, 2021, 606, 120877.	5.2	35

#	ARTICLE	IF	CITATIONS
19	Advances and challenges in nintedanib drug delivery. Expert Opinion on Drug Delivery, 2021, 18, 1687-1706.	5.0	3
20	Development of lapatinib nanosponges for enhancing bioavailability. Journal of Drug Delivery Science and Technology, 2021, 65, 102684.	3.0	13
21	Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers. International Journal of Pharmaceutics, 2021, 608, 121119.	5.2	2
22	Combined experimental and molecular dynamics investigation of 1D rod-like asphaltene aggregation in toluene-hexane mixture. Journal of Molecular Liquids, 2021, 339, 116812.	4.9	9
23	Identification of novel small molecule inhibitors for endoplasmic reticulum oxidoreductase 1 β (ERO1 β) enzyme: structure-based molecular docking and molecular dynamic simulation studies. Journal of Biomolecular Structure and Dynamics, 2021, , 1-15.	3.5	1
24	Design and development of surface modified epigallocatechin 3-gallate NanoCubogel for localized delivery to oral submucous fibrosis therapy. Journal of Drug Delivery Science and Technology, 2021, 66, 102911.	3.0	2
25	Molecular modeling piloted analysis for semicarbazone derivative of curcumin as a potent Abl-kinase inhibitor targeting colon cancer. 3 Biotech, 2021, 11, 506.	2.2	5
26	Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II). Journal of Biomolecular Structure and Dynamics, 2020, 38, 3772-3789.	3.5	11
27	Antimicrobial peptide polymers: no escape to ESKAPE pathogensâ€”a review. World Journal of Microbiology and Biotechnology, 2020, 36, 131.	3.6	53
28	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. Pharmaceutics, 2020, 12, 524.	4.5	22
29	Asphaltene Aggregation in Aqueous Solution Using Different Water Models: A Classical Molecular Dynamics Study. ACS Omega, 2020, 5, 16530-16536.	3.5	14
30	Recent advances in the development of asenapine formulations. Expert Opinion on Drug Delivery, 2020, 17, 1377-1393.	5.0	6
31	Multiple approaches for achieving drug solubility: an in silico perspective. Drug Discovery Today, 2020, 25, 1206-1212.	6.4	28
32	Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19. F1000Research, 2020, 9, 1166.	1.6	49
33	Nanoemulgel: A Promising Phase in Drug Delivery. Current Pharmaceutical Design, 2020, 26, 279-291.	1.9	22
34	The Beginning of a New Era: Artificial Intelligence in Healthcare. Advanced Pharmaceutical Bulletin, 2020, 11, 414-425.	1.4	12
35	In Silico Drug Repurposing of Penicillins to Target Main Protease M ^{pro} of SARS-CoV-2. Pharmaceutical Sciences, 2020, 26, S52-S62.	0.2	3
36	Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension. Journal of Molecular Liquids, 2019, 293, 111469.	4.9	23

#	ARTICLE	IF	CITATIONS
37	2,5-Dimethyl-4-hydroxy-3(2H)-furanone as an Anti-biofilm Agent Against Non-Candida albicans Candida Species. Mycopathologia, 2019, 184, 403-411.	3.1	14
38	In Vitro Evaluation of Substantivity, Staining Potential, and Biofilm Reduction of Guava Leaf Extract Mouth Rinse in Combination with its Anti-Inflammatory Effect on Human Gingival Epithelial Keratinocytes. Materials, 2019, 12, 3903.	2.9	10
39	Evaluation of a mouthrinse containing guava leaf extract as part of comprehensive oral care regimen- a randomized placebo-controlled clinical trial. BMC Complementary and Alternative Medicine, 2019, 19, 327.	3.7	16
40	Computational modeling for formulation design. Drug Discovery Today, 2019, 24, 781-788.	6.4	59
41	Anti-aging and Sunscreens: Paradigm Shift in Cosmetics. Advanced Pharmaceutical Bulletin, 2019, 9, 348-359.	1.4	69
42	Host-guest interaction study of Efavirenz with hydroxypropyl-β-cyclodextrin and L-arginine by computational simulation studies: Preparation and characterization of supramolecular complexes. Journal of Molecular Liquids, 2018, 259, 55-64.	4.9	18
43	Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. Journal of Drug Delivery Science and Technology, 2018, 44, 181-189.	3.0	39
44	Localized In Situ Nanoemulgel Drug Delivery System of Quercetin for Periodontitis: Development and Computational Simulations. Molecules, 2018, 23, 1363.	3.8	49
45	Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances. Pharmaceutics, 2018, 10, 118.	4.5	573
46	A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy. Materials Science and Engineering C, 2017, 75, 535-544.	7.3	12
47	Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies. Molecular Pharmaceutics, 2017, 14, 1231-1242.	4.6	64
48	Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting. Life Sciences, 2017, 183, 11-20.	4.3	22
49	A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies. International Journal of Nanomedicine, 2017, Volume 12, 4921-4935.	6.7	29
50	Development of risperidone liposomes for brain targeting through intranasal route. Life Sciences, 2016, 163, 38-45.	4.3	85
51	PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. Journal of Liposome Research, 2016, 26, 28-46.	3.3	30
52	Lymphatic Delivery of Anti-HIV Drug Nanoparticles. Recent Patents on Nanotechnology, 2016, 10, 116-127.	1.3	8
53	AN OVERVIEW OF NOVEL AND CONTROLLED DRUG DELIVERY SYSTEMS. Indian Drugs, 2016, 53, 5-12.	0.1	0
54	Development and evaluation of sunscreen creams containing morin-encapsulated nanoparticles for enhanced UV radiation protection and antioxidant activity. International Journal of Nanomedicine, 2015, 10, 6477.	6.7	55

#	ARTICLE	IF	CITATIONS
55	Novel pH-sensitive IPNs of polyacrylamide-g-gum ghatti and sodium alginate for gastro-protective drug delivery. International Journal of Biological Macromolecules, 2015, 75, 133-143.	7.5	39
56	Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model. Life Sciences, 2015, 141, 143-155.	4.3	27
57	Gastroretentive Pulsatile Release Tablets of Lercanidipine HCl: Development, Statistical Optimization, and In Vitro and In Vivo Evaluation. Scientific World Journal, The, 2014, 2014, 1-13.	2.1	7
58	Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: Statistical optimization, in vitro and in vivo evaluation. Drug Delivery, 2014, 21, 509-518.	5.7	27
59	Optimization of Chronomodulated Delivery System Coated with a Blend of Ethyl Cellulose and Eudragit L100 by Central Composite Design: In Vitro and In Vivo Evaluation. Journal of Pharmaceutical Innovation, 2014, 9, 95-105.	2.4	11
60	Formulation, Characterization and In Vivo Evaluation of Self-Nanoemulsifying Drug Delivery System for Oral Delivery of Valsartan. Current Nanoscience, 2014, 10, 263-270.	1.2	6
61	Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: Application to preclinical pharmacokinetics. Journal of Young Pharmacists, 2013, 5, 133-138.	0.2	8
62	Pharmaceutical applications of radio-frequency identification. Systematic Reviews in Pharmacy (discontinued), 2012, 3, 24.	0.2	2
63	Sonophoresis-mediated permeation and retention of peptide dendrimers across human epidermis. Skin Research and Technology, 2012, 18, 101-107.	1.6	28
64	Novel interpenetrated polymer network microbeads of natural polysaccharides for modified release of water soluble drug: in-vitro and in-vivo evaluation. Journal of Pharmacy and Pharmacology, 2012, 64, 530-540.	2.4	48
65	Formulation of Gliclazide Encapsulated Chitosan Nanoparticles: In Vitro and In Vivo Evaluation. Special Publication - Royal Society of Chemistry, 2012, , 77-85.	0.0	3
66	Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation. Journal of Materials Science: Materials in Medicine, 2011, 22, 865-878.	3.6	28
67	Controlled release chitosan microspheres of mirtazapine: In vitro and in vivo evaluation. Archives of Pharmacal Research, 2011, 34, 1919-1929.	6.3	17
68	Chronotherapeutic drug delivery for early morning surge in blood pressure: A programmable delivery system. Journal of Controlled Release, 2009, 136, 125-131.	9.9	41
69	Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of Zidovudine. Journal of Microencapsulation, 2009, 26, 214-222.	2.8	50
70	Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. Pharmaceutical Development and Technology, 2009, 14, 199-207.	2.4	41
71	Multiparticulate Drug Delivery System of Aceclofenac: Development and In Vitro Studies. Drug Development and Industrial Pharmacy, 2009, 35, 252-258.	2.0	11
72	Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan-based solvent change approach. International Journal of Pharmaceutics, 2008, 350, 279-290.	5.2	75

#	ARTICLE	IF	CITATIONS
73	Chitosan and Enteric Polymer Based Once Daily Sustained Release Tablets of Aceclofenac: In Vitro and In Vivo Studies. AAPS PharmSciTech, 2008, 9, 651-9.	3.3	17
74	Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 674-683.	4.3	49